B. Riley Raises Earnings Estimates for PDS Biotechnology

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Research analysts at B. Riley lifted their Q1 2025 earnings estimates for shares of PDS Biotechnology in a research note issued to investors on Monday, April 21st. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.31) for the quarter, up from their prior forecast of ($0.34). The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.20) per share. B. Riley also issued estimates for PDS Biotechnology's Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at $0.10 EPS.

Separately, HC Wainwright decreased their price objective on PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $9.00.

PDS Biotechnology Stock Up 2.8 %

NASDAQ:PDSB traded up $0.04 during trading hours on Thursday, reaching $1.28. The company's stock had a trading volume of 67,166 shares, compared to its average volume of 485,155. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The company has a market capitalization of $57.88 million, a P/E ratio of -1.10 and a beta of 1.50. The stock has a 50 day moving average price of $1.20 and a two-hundred day moving average price of $1.79. PDS Biotechnology has a 12 month low of $0.85 and a 12 month high of $4.42.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.08.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company's stock worth $1,586,000 after acquiring an additional 37,142 shares during the last quarter. Blair William & Co. IL grew its position in PDS Biotechnology by 29.4% during the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company's stock worth $257,000 after purchasing an additional 35,757 shares during the last quarter. Renaissance Technologies LLC increased its stake in PDS Biotechnology by 331.0% during the 4th quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock valued at $163,000 after purchasing an additional 76,800 shares in the last quarter. Two Sigma Investments LP raised its holdings in shares of PDS Biotechnology by 273.5% in the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock worth $107,000 after buying an additional 48,132 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of PDS Biotechnology during the fourth quarter valued at $89,000. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.